补体参与儿童肾脏疾病发病机制的再认识

doi:10.12372/jcp.2024.23e0595

Abstract

Abstract:

Complement is an important component of innate immunity, as well as a bridge to regulate adaptive immunity. It is an important substance that mediates cellular inflammatory response and induces apoptosis. The cascade of the complement response is stictly regulated by the stringent control of the complennent regulatory proteins. Should the complement overactivated or regulate abnormally, it can cause damage to the host cells. In the glomerular microenvironment, dysregulation of the complement system can lead to C3 glomerulopathy and atypical hemolytic uremic syndrome. In addition, complement is also hyperactivated in many other inflammatory kidney diseases, such as ANCA-associated glomerulonephritis, lupus nephritis, IgA nephropathy, membranous nephropathy, and diabetic nephropathy. In addition, it may mediate renal allograft injury by playing a role in ischemia-reperfusion injury and rejection. This article reviews the role of complement in the pathogenesis of glomerular diseases and related targeted therapy.

Key words: complement, kidney disease, targeted Therapy

WANG Peipei, ZHANG Pei, GAO Chunlin, XIA Zhengkun. Re-recognition of the complement involvement in the pathogenesis of kidney diseases in children[J].Journal of Clinical Pediatrics, 2024, 42(5): 467-473.

References 58

[1]	Borza DB. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation[J]. Matrix Biol, 2017(57-58): 299-310.
[2]	Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling ariadne's thread into the labyrinth of complement therapeutics[J]. Front Immunol, 2019, 10: 337. doi: 10.3389/fimmu.2019.00337 pmid: 30891033
[3]	Leon J, LeStang MB, Sberro-Soussan R, et al. Complement-driven hemolytic uremic syndrome[J]. Am J Hematol, 2023, 98(Suppl 4): S44-S56.
[4]	Blasco M, Guillén-Olmos E, Diaz-Ricart M, et al. Complement mediated endothelial damage in thrombotic microangiopathies[J]. Front Med (Lausanne), 2022, 9: 811504.
[5]	Özçakar ZB, Ozaltin F, Gülhan B, et al. Transplantation in pediatric aHUS within the era of eculizumab therapy[J]. Pediatr Transplant, 2021, 25(3): e13914.
[6]	Tang ZC, Hui H, Shi C, et al. New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses[J]. Ren Fail, 2023, 45(1): 2231264. doi: 10.1080/0886022X.2023.2231264
[7]	Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study[J]. Blood, 2021, 137(18): 2438-2449. doi: 10.1182/blood.2020009280 pmid: 33270832
[8]	Palma LMP, Eick RG, Dantas GC, et al. Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab[J]. Clin Kidney J, 2021, 14(4): 1126-1135. doi: 10.1093/ckj/sfaa062 pmid: 33841858
[9]	Jodele S, Dandoy CE, Lane A, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab[J]. Blood, 2020, 135(13): 1049-1057. doi: 10.1182/blood.2019004218 pmid: 31932840
[10]	Heiderscheit AK, Hauer JJ, Smith RJH. C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease[J]. Am J Med Genet C Semin Med Genet, 2022, 190(3): 344-357. doi: 10.1002/ajmg.c.v190.3
[11]	Kant S, Kronbichler A, Sharma P, et al. Advances in understanding of pathogenesis and treatment of immune-mediated kidney disease: a review[J]. Am J Kidney Dis, 2022, 79(4): 582-600. doi: 10.1053/j.ajkd.2021.07.019
[12]	Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-a new look at an old entity[J]. N Engl J Med, 2012, 366(12): 1119-1131. doi: 10.1056/NEJMra1108178
[13]	Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4): 753-779. doi: 10.1016/j.kint.2021.05.015 pmid: 34556300
[14]	Michels M, Wijnsma KL, Kurvers RAJ, et al. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort[J]. Pediatr Nephrol, 2022, 37(3): 601-612. doi: 10.1007/s00467-021-05221-6
[15]	Günay N, Dursun İ, Gökçe İ, et al. Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?[J]. Pediatr Nephrol, 2024, 39(5): 1435-1446. doi: 10.1007/s00467-023-06231-2
[16]	Caravaca-Fontán F, Lucientes L, Cavero T, et al. Update on C3 glomerulopathy: a complement-mediated disease[J]. Nephron, 2020, 144(6): 272-280. doi: 10.1159/000507254
[17]	Chauvet S, Hauer JJ, Petitprez F, et al. Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy[J]. Kidney Int, 2022, 102(4): 904-916. doi: 10.1016/j.kint.2022.05.027 pmid: 35752323
[18]	Pinarbasi AS, Dursun I, Poyrazoglu MH, et al. Evaluation of the children with C3 glomerulopathy[J]. Saudi J Kidney Dis Transpl, 2020, 31(1): 79-89. doi: 10.4103/1319-2442.279964 pmid: 32129200
[19]	Zotta F, Diomedi-Camassei F, Gargiulo A, et al. Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis[J]. Pediatr Nephrol, 2023, 38(12): 4197-4201. doi: 10.1007/s00467-023-06035-4 pmid: 37306717
[20]	Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference[J]. Kidney Int, 2017, 91(3): 539-551. doi: S0085-2538(16)30604-4 pmid: 27989322
[21]	Mazzariol M, Manenti L, Vaglio A. The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target[J]. Curr Opin Rheumatol, 2023, 35(1): 31-36. doi: 10.1097/BOR.0000000000000914
[22]	Moiseev S, Lee JM, Zykova A, et al. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis[J]. Clin Exp Immunol, 2020, 202(3): 394-402. doi: 10.1111/cei.13498
[23]	Zhang P, Yan SJ, Hu J, et al. EXPRESS: Clinical outcomes and clinico-pathological correlations in children with MPO-ANCA-associated glomerulonephritis showing renal arteritis[J]. J Investig Med, 2024: 10815589241248073.
[24]	Johansson L, Berglin E, Eriksson O, et al. Complement activation prior to symptom onset in myeloperoxidase ANCA-associated vasculitis but not proteinase 3 ANCA associated vasculitis - A Swedish biobank study[J]. Scand J Rheumatol, 2022, 51(3): 214-219. doi: 10.1080/03009742.2021.1989814 pmid: 35048784
[25]	García L, Pena CE, Maldonado R, et al. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study[J]. Clin Rheumatol, 2019, 38(10): 2819-2824. doi: 10.1007/s10067-019-04636-9 pmid: 31222573
[26]	Antovic A, Mobarrez F, Manojlovic M, et al. Microparticles expressing myeloperoxidase and complement C3a and C5a as markers of renal involvement in antineutrophil cytoplasmic antibody-associated vasculitis[J]. J Rheumatol, 2020, 47(5): 714-721. doi: 10.3899/jrheum.181347 pmid: 31371653
[27]	Turgeon D, Bakowsky V, Baldwin C, et al. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum[J]. Rheumatology (Oxford), 2023, 62(8): 2646-2651. doi: 10.1093/rheumatology/kead087
[28]	Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis[J]. N Engl J Med, 2021, 384(7): 599-609. doi: 10.1056/NEJMoa2023386
[29]	Zhang P, Yang X, Fang X, et al. Anti-C1q antibodies in lupus nephritis children with glomerular microthrombosis[J]. Nephrology (Carlton), 2023, 28(9): 485-494. doi: 10.1111/nep.v28.9
[30]	Ye B, Chen B, Guo C, et al. C5a-C5aR1 axis controls mitochondrial fission to promote podocyte injury in lupus nephritis[J]. Mol Ther, 2024: S1525-0016(24)00144-8.
[31]	Chen K, Deng Y, Shang S, et al. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice[J]. Biomed Pharmacother, 2022, 153: 113433. doi: 10.1016/j.biopha.2022.113433
[32]	Wright RD, Bannerman F, Beresford MW, et al. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic micro-angiopathy[J]. BMC Nephrol, 2020, 21(1): 245. doi: 10.1186/s12882-020-01888-5
[33]	Al Hussain T, Hussein MH, Al Mana H, et al. Patho-physiology of IgA nephropathy[J]. Adv Anat Pathol, 2017, 24(1): 56-62. pmid: 27941542
[34]	Barratt J, Lafayette RA, Zhang H, et al. IgA nephropathy: the lectin pathway and implications for targeted therapy[J]. Kidney Int, 2023, 104(2): 254-264. doi: 10.1016/j.kint.2023.04.029 pmid: 37263354
[35]	Mizerska-Wasiak M, Such-Gruchot A, Cichoń-Kawa K, et al. The role of complement component C3 activation in the clinical presentation and prognosis of IgA nephropathy-A National Study in Children[J]. J Clin Med, 2021, 10(19):4405. doi: 10.3390/jcm10194405
[36]	Kistler AD, Salant DJ. Complement activation and effector pathways in membranous nephropathy[J]. Kidney Int, 2024, 105(3): 473-483. doi: 10.1016/j.kint.2023.10.035
[37]	Gao S, Cui Z, Zhao MH. Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy[J]. J Am Soc Nephrol, 2022, 33(9): 1742-1756. doi: 10.1681/ASN.2021101384 pmid: 35777783
[38]	Haddad G, Lorenzen JM, Ma H, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy[J]. J Clin Invest, 2021, 131(5):e140453. doi: 10.1172/JCI140453
[39]	Seifert L, Zahner G, Meyer-Schwesinger C, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy[J]. Nat Commun, 2023, 14(1): 473. doi: 10.1038/s41467-023-36068-0 pmid: 36709213
[40]	Zhang Q, Bin S, Budge K, et al. C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy[J]. JCI Insight, 2024, 9(4): e172976.
[41]	Zheng JM, Ren XG, Jiang ZH, et al. Lectin-induced renal local complement activation is involved in tubular interstitial injury in diabetic nephropathy[J]. Clin Chim Acta, 2018, 482: 65-73. doi: 10.1016/j.cca.2018.03.033
[42]	Flyvbjerg A. The role of the complement system in diabetic nephropathy[J]. Nat Rev Nephrol, 2017, 13(5): 311-318. doi: 10.1038/nrneph.2017.31 pmid: 28262777
[43]	Pesce F, Stea ED, Rossini M, et al. Glomerulonephritis in AKI: from pathogenesis to therapeutic intervention[J]. Front Med (Lausanne), 2020, 7: 582272.
[44]	Huang J, Cui Z, Gu QH, et al. Complement activation profile of patients with primary focal segmental glomerulosclerosis[J]. PLoS One, 2020, 15(6): e0234934.
[45]	Wang C, Wang Z, Zhang W. The potential role of complement alternative pathway activation in hypertensive renal damage[J]. Exp Biol Med (Maywood), 2022, 247(9): 797-804. doi: 10.1177/15353702221091986
[46]	Nithagon P, Cortazar F, Shah SI, et al. Eculizumab and complement activation in anti-glomerular basement membrane disease[J]. Kidney Int Rep, 2021, 6(10): 2713-2717. doi: 10.1016/j.ekir.2021.07.001 pmid: 34622110
[47]	Golshayan D, Schwotzer N, Fakhouri F, et al. Targeting the complement pathway in kidney transplantation[J]. J Am Soc Nephrol, 2023, 34(11): 1776-1792. doi: 10.1681/ASN.0000000000000192 pmid: 37439664
[48]	Santarsiero D, Aiello S. The complement system in kidney transplantation[J]. Cells, 2023, 12(5):791. doi: 10.3390/cells12050791
[49]	Vonbrunn E, Büttner-Herold M, Amann K, et al. Complement inhibition in kidney transplantation: where are we now?[J]. BioDrugs, 2023, 37(1): 5-19. doi: 10.1007/s40259-022-00567-1
[50]	Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney International, 2021, 100(4): S1-S276.
[51]	Rosenblad T, Rebetz J, Johansson M, et al. Eculizumab treatment for rescue of renal function in IgA nephropathy[J]. Pediatr Nephrol, 2014, 29(11): 2225-2228. doi: 10.1007/s00467-014-2863-y pmid: 24924752
[52]	McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine[J]. MMWR Morb Mortal Wkly Rep, 2017, 66(27): 734-737. doi: 10.15585/mmwr.mm6627e1
[53]	Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39. doi: 10.1007/s00467-015-3076-8 pmid: 25859752
[54]	Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities[J]. Pediatr Nephrol, 2024, 39(5): 1387-1404. doi: 10.1007/s00467-023-06120-8
[55]	Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment[J]. Kidney Int, 2020, 97(6): 1287-1296. doi: S0085-2538(20)30152-6 pmid: 32299680
[56]	Lee A. Avacopan: first approval[J]. Drugs, 2022, 82(1): 79-85. doi: 10.1007/s40265-021-01643-6
[57]	Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome[J]. Kidney Int, 2018, 94(2): 408-418. doi: S0085-2538(18)30243-6 pmid: 29907460
[58]	Lapeyraque AL, Bitzan M, Al-Dakkak I, et al. Clinical Characteristics and outcome of Canadian patients diagnosed with atypical hemolytic uremic syndrome[J]. Can J Kidney Health Dis, 2020, 7: 2054358119897229.

Re-recognition of the complement involvement in the pathogenesis of kidney diseases in children

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 58

Related Articles 11

Metrics

Comments

Recommended 0

[1]	ZHANG Pei, GAO Chunlin, XIA Zhengkun. Comments on KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease of Children [J]. Journal of Clinical Pediatrics, 2022, 40(6): 469-474.
[2]	KUANG Qianhuining, GAO Chunlin, ZHU Hong, YANG Xiao, PENG Yingchao, XIA Zhengkun. Comparison of different estimation formulas of glomerular filtration rate in children aged 15-18 years with chronic kidney disease [J]. Journal of Clinical Pediatrics, 2022, 40(12): 905-911.
[3]	FENG Shipin, WANG Li, LIU Xi, et al. Clinical and pathological analysis of 1002 children with chronic kidney disease [J]. Journal of Clinical Pediatrics, 2021, 39(2): 87-.
[4]	SUN Xiaopeng, LIN Yi, NIE Nana, et al. Chronic kidney disease due to variation of PAX2 gene: report of two cases and literature review [J]. Journal of Clinical Pediatrics, 2021, 39(12): 905-.
[5]	FU Qingying, LIU Yang, WANG Weihua, et al. The relationship of infection with blood pressure and immunological indicators in children with IgA nephropathy [J]. Journal of Clinical Pediatrics, 2020, 38(6): 410-.
[6]	WANG Caiyun, SONG Dan, SONG Chundong, et al. Clinical analysis of kidney disease combined with posterior reversible encephalopathy syndrome in 6 children [J]. Journal of Clinical Pediatrics, 2020, 38(1): 31-.
[7]	SUN Hui, XUE Ying, HUANG Feng, WU Haiying, XIE Rongrong, WANG Fengyun, CHEN Xiuli, CHEN Ting, CHEN Linqi. Clinical significance of glomerular hyperfiltration in assessment of early renal damage in childhood type 1 diabetes [J]. , 2018, 36(8): 575-.
[8]	ZHAO Yang. New therapy of childhood refractory/relapsed acute lymphoblastic leukemia [J]. , 2018, 36(8): 639-.
[9]	ZHANG Hongwen. Some reflections on pediatric renal diseases　 [J]. , 2018, 36(6): 401-.
[10]	XIAO Huijie, XU Ke, DING Jie. New understanding of complement in childhood immune and/or inflammatory renal diseases [J]. , 2015, 33(6): 504-.
[11]	ZHANG Hongbo, HUANG Jianping. Transition from endocapillary proliferative glomerulonephritis to membrane proliferative glomerulonephritis: a case report [J]. , 2015, 33(3): 247-.